Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya

Mar 03, 04:30 PM
Headliner
Share
Subscribe
In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.
Share
Subscribe
Next
Pharma Pulse: FDA Expands Pediatric Juxtapid Approval and Novo Nordisk Invests €432M in Oral GLP-1 Scaling
Top episodes
Overcoming Supply Chain Challenges
by Pharma Pulse
Incorporating AI into Commercialization Plans
by Pharma Pulse
The Capabilities of a 3PL Provider
by Pharma Pulse